This increase was primarily due to increases in personal costs, including share-based compensation expense of $1.5 million, resulting from increases in headcount in our clinical and marketing teams, increases in travel expenses of $0.3 million, and increases in marketing activities of $0.2 million.

Mar 1, 2023 / CFO / receipt, needs a key / Danilo De Alessandro, CFO | earnings call 2023-03-01 | transcript 34436d66-0674-4de9-a590-5acd6d3cb312 | chars 4860-5159 | segment 5